KennethMKernenMD

Urology • Troy, MI

Minimally Invasive Surgery, Surgical Oncology

Associate Professor of Urology, Oakland University-William Beaumont Medical School. Director of Urology, Beaumont Troy

Join to view full profile

Dr. Kernen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kernen's full profile

Already have an account?

Office
130 Town Center Drive
Suite 101
Troy, MI 48084
Phone+1 248-740-0670

Education & Training

Corewell Health East Beaumont (Royal Oak)Residency, Urology, 1995 - 1999
Corewell Health East Beaumont (Royal Oak)Residency, Surgery, 1993 - 1995
Wayne State University School of MedicineClass of 1993

Certifications & Licensure

MI State Medical License 2000 - 2025
American Board of Urology Urology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Top MD Consumers Checkbook

Clinical Trials

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jan 01
Terminated
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer Start of enrollment: 2021 May 05
Completed
Phase 3

Publications & Presentations

PubMed

Temporarily implanted nitinol device versus prostatic urethral lift for minimally invasive surgical treatment of benign prostatic hyperplasia with lower urinary tract ...
Kenneth M Kernen, Shalina Omar, Bradley Goodnight, Paul Skodny, Stuart Bruce
The Canadian Journal of Urology. 2023-10-01
4 citations
Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients With Non-Metastatic Castration-Resistant Prostate Cancer.
Benjamin Lowentritt, Gordon Brown, Dominic Pilon, Lorie Ellis, Guillaume Germain
Urology. 2022-08-01
1 citations
Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer
Leander Van Neste, Kirk J. Wojno, Ricardo Henao, Shrikant Mane, Howard J. Korman
Cells. 2021-09-28

Press Mentions

Tavanta Therapeutics Announces Completion of Enrollment in Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate CancerAugust 1st, 2022
Temporary Implant Provides Relief for Men with Enlarged ProstateOctober 19th, 2021
iTind System for BPH Treatment Reaches Two Major Milestones: First Commercial Treatments and CMS Reimbursement Code AssignedNovember 17th, 2020